Predicted protein targets (top 2)
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL17683276 | 0.91 | LRRK2 (0.41) | LRRK2PTK2 | |
| SCHEMBL17682942 | 0.87 | EGFR (0.46) | LRRK2 | |
| SCHEMBL19532546 | 0.83 | LRRK2 (0.36) | LRRK2 | |
| SCHEMBL19540761 | 0.83 | LRRK2 (0.44) | LRRK2 | |
| SCHEMBL17683376 | 0.81 | LRRK2 (0.38) | LRRK2PTK2 | |
| SCHEMBL17683380 | 0.80 | LRRK2 (0.41) | LRRK2 | |
| SCHEMBL19254675 | 0.80 | EGFR (0.44) | LRRK2 | |
| SCHEMBL23729044 | 0.78 | LRRK2 (0.42) | LRRK2PTK2 | |
| SCHEMBL17682938 | 0.78 | EGFR (0.41) | LRRK2 | |
| SCHEMBL23729091 | 0.78 | EGFR (0.46) | — |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20170313714-A1 | EGFR INHIBITOR, PREPARATION METHOD AND USE THEREOF | SHANGHAI HANSOH BIOMEDICAL CO., LTD. (CN) | 2017-11-02 | — | — | US | disclosed |
| EP-3205650-A1 | EGFR INHIBITOR, AND PREPARATION AND APPLICATION THEREOF | Shanghai Hansoh Biomedical Co., Ltd. (CN) | 2017-08-16 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20170313714-A1 | EGFR INHIBITOR, PREPARATION METHOD AND USE THEREOF | EGFR, ERBB2, ERBB4 | LRRK2 266/4885PTK2 857/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.